Income Statement
TAYSHA GENE THERAPIES, INC.
TSHA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
9.77 | 8.33 | 15.45 | 2.50 | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - |
|
Gross Profit
|
9.77 | 8.33 | 15.45 | 2.50 | - | - |
|
Operating Expenses
|
120.27 | 99.79 | 87.89 | 164.95 | 173.27 | 43.00 |
|
Research & Development
|
86.40 | 66.00 | 56.78 | 91.17 | 131.94 | 31.89 |
|
Selling, General & Administrative
|
33.87 | 28.95 | 30.05 | 37.36 | 41.32 | 11.11 |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-110.50 | -91.46 | -72.44 | -162.45 | -173.27 | -43.00 |
|
Non-Operating Income
|
1.50 | 2.16 | -39.13 | -3.57 | -1.26 | -17.01 |
|
Interest Income
|
9.22 | 6.94 | - | - | - | - |
|
Interest Expense
|
- | - | 5.00 | 3.80 | 1.43 | 0.03 |
|
Other Non-Op Income / Expense
|
-0.29 | -0.11 | -0.05 | - | - | - |
|
Income Before Tax
|
- | - | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - |
|
Net Income
|
-109.00 | -89.30 | -111.57 | -166.01 | -174.52 | -60.01 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-110.50 | -91.46 | -72.44 | -162.45 | -173.27 | -43.00 |
|
Earnings Per Share (Basic)
|
-0.34 | -0.36 | -0.96 | -3.78 | - | - |
|
Diluted EPS
|
-0.34 | -0.36 | -0.96 | -3.78 | - | - |
|
Weighted Average Shares
|
319.71 | 250.13 | 116.12 | 43.95 | - | - |
|
Diluted Weighted Avg Shares
|
319.71 | 250.13 | 116.12 | 43.95 | - | - |
|
Comprehensive Income
|
- | - | - | - | - | - |